The Latest Biotechnology / Pharmaceuticals Articles from Streetwise Reports


Neuroscientist With Research Program Joins Biotech's SAB

  ()
ProMIS Neurosciences appointed to its science advisory board Canada-based Dr. Cheryl Wellington, professor, neuroscientist and head of a globally recognized neuro research program.
Tags:  Biotechnology / Pharmaceuticals

Co. Meets Goals in COVID Drug Trial

  ()
Todos Medical has closed a Phase 2 trial of its antiviral 3CL protease inhibitor Tollovir after getting positive interim data.
Tags:  Biotechnology / Pharmaceuticals

Pharma to Test if DMT Helps Brain Regain Function Post Stroke

  ()
During Streetwise Live! on Jan. 27, 2022, representatives of Algernon Pharmaceuticals discussed the use of the psychedelic DMT in stroke sufferers. On the broadcast were Algernon CEO Christopher Moreau and consultants to the firm, Dr. David Nutt and Dr. Rick Strassman.
Tags:  Biotechnology / Pharmaceuticals

Possible Treatment for CRC Shows Promise

Research Report
  ()
New trial results of Exelixis' cabozantinib in colorectal cancer are encouraging for further development of the biopharma's XL902 in the indication, noted an H.C. Wainwright & Co. report.
Tags:  Biotechnology / Pharmaceuticals

‘Strong Data’ Expected From Todos Medical Data Lock

Contributed Opinion
  ()
Todos Medical is set to take on the dominant players in oral antivirals for mild to moderate COVID-19, Pfizer Inc. and Merck & Co. Inc., with "strong data" expected to be released soon for its drug Tollovir.
Tags:  Biotechnology / Pharmaceuticals

Fourth COVID-19 Vaccine Shot Shown Less Effective

Research Report
  ()
BioNTech aims to develop a COVID-19 vaccine targeting the Omicron variant, noted an H.C. Wainwright & Co. report.
Tags:  Biotechnology / Pharmaceuticals

FDA Gives Fast Track Status to Firm for Adrenal Rescue Pen

Research Report
  ()
Now with fast track status and positive Phase 1 study results, Antares Pharma plans to advance its ATRS-1902 product candidate into a second trial in Q2/22, noted a Ladenburg Thalmann report.
Tags:  Medical DevicesBiotechnology / Pharmaceuticals

First NSCLC Patient Dosed With Trial Therapeutic

Research Report
  ()
Two recent Vaccitech events, the MAGE trial initial dosing and the acquisition of Avidea's SNAPvax technology, bode well for its ChAdOx1-MVA platform, noted an H.C. Wainwright & Co. report.
Tags:  Biotechnology / Pharmaceuticals

Fund Triples Holding of Drug Repurposing Firm

  ()
Several events slated to happen this year could boost Algernon Pharmaceuticals' share price, noted an AlphaNorth Partners Fund performance report.
Tags:  Biotechnology / Pharmaceuticals

Derm Biopharma Named Top Growth Pick For 2022

Research Report
  ()
Journey Medical should increase 2022 and 2023 revenue by at least 30% such that it could turn a profit in 2024, noted a ROTH Capital Partners report.
Tags:  Biotechnology / Pharmaceuticals

This Pharmaceutical Company Has a Brilliant Concept

Contributed Opinion
  ()
Algernon Pharmaceuticals is a clinical-stage, small biotech that boasts a massive pipeline of lower risk and efficient drugs. Catalysts abound with this genius repurposing company.
Tags:  Biotechnology / Pharmaceuticals

Ph1 Trial Results of Dementia Drug Positive

Research Report
  ()
Anavex Life Sciences' study of Anavex 3-71 in frontotemporal dementia met primary and secondary safety endpoints, noted a Dawson James Securities report.
Tags:  Biotechnology / Pharmaceuticals

Biotech Co. Partners With Life Sciences Firms

Research Report
  ()
2seventy entered agreements with Novo Nordisk and Genevant to get an in vivo gene editing treatment for hemophilia A developed, noted a Wedbush report.
Tags:  Biotechnology / Pharmaceuticals

Enrollment Done for COVID-19 Drug Trial

Research Report
  ()
Part 2 of First Wave BioPharma's RESERVOIR trial of niclosamide to remove the SARS-CoV-2 virus from the GI tract is underway, noted a ROTH Capital Partners report.
Tags:  Biotechnology / Pharmaceuticals

2022 to Be Catalyst Rich for Biopharma

Research Report
  ()
The potential stock-moving events for Infinity Pharmaceuticals this year include the launch of two clinical trials and readouts from four studies, noted an H.C. Wainwright & Co. report.
Tags:  Biotechnology / Pharmaceuticals

Co.'s samRNA Vaccines Protect Better Against COVID Variants

Research Report
  ()
Gritstone bio Inc.'s lower-dose samRNA vaccines include a broader immune response to SARS-CoV-2 and may provide better protection against emerging variants. BTIG research has issued a "Buy" rating for Gritstone bio.
Tags:  Biotechnology / Pharmaceuticals

AI Driven Drug Firm Partners With Merck

  ()
Shares of Absci Corp. rose 18% after the company reported it is collaborating with Merck & Co. to create enzymes using its deep-learning Integrated Drug Creation™ platform and Bionic Protein™ technologies.
Tags:  Biotechnology / Pharmaceuticals

Co. Partners to Test New Cancer Vaccines

Research Report
  ()
Genocea Biosciences Inc. is teaming up with Janssen Biotech to explore the immunogenicity of neoantigens and the role and impact of Inhibigens™ in potential vaccine therapies for cancer. H.C. Wainwright & Co. advised that it currently has a "Buy" rating on Genocea.
Tags:  Biotechnology / Pharmaceuticals

Co. Plans to Make 100M Rapid COVID Tests Monthly

Research Report
  ()
Biopharmaceutical firm Sorrento Therapeutics Inc. plans to mobilize a fully automated assembly line in San Diego, Calif., capable of producing 6 million rapid antigen detection COVISTIX testing units per month starting in Q1/22.
Tags:  Biotechnology / Pharmaceuticals

New Muscular Dystrophy Drug Shows Promise

  ()
Edgewise Therapeutics shares traded 24% higher after the company reported its EDG-5506 significantly lowered muscle damage biomarkers in adults after just two weeks of dosing in its Becker muscular dystrophy trial.
Tags:  Biotechnology / Pharmaceuticals

Chen Lin's Top 6 Investment Ideas

  ()
In a recent interview with Streetwise Reports, family assets manager and contributing writer, Chen Lin, shared the six (mostly mid-cap) companies that are his top investment picks for 2022.
Tags:  GoldBiotechnology / Pharmaceuticals

Lead Cancer Drug Gets Fast Tracked

  ()
Shares of Genprex Inc. traded 165% higher after the company reported the U.S. FDA has awarded Fast Track Designation for its REQORSA™ Immunogene Therapy for use in combination with Merck & Co.'s Keytruda® for non-small cell lung cancer treatment.
Tags:  Biotechnology / Pharmaceuticals

Showing Results: 51 to 75 of 105 Prev Next

Get Our Streetwise Reports Newsletter Free and be the first to know!

A valid email address is required to subscribe

More Experts

"This is considered to be a good time to buy DEFN or add to positions." ❭
– Clive Maund, CliveMaund.com
"WCU signed an LOI for construction of a pipeline to provide seawater." ❭
– Taylor Combaluzier, Red Cloud Securities
"SEA increased M&I resources at Mitchell and East Mitchell by 16%." ❭
– David Talbot, Red Cloud Securities
"It is great to see 15m at 3.1 g/t Au at surface at TLG's Southwest." ❭
– Brock Salier, Sprott Equity Research
"REYG reported first drill results of 7.85m of 3.95 g/t gold." ❭
– Chen Lin, What Is Chen Buying? What Is Chen Selling?